Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SIRT6c
- Development stage
- Preclinical
- Lead developer
- GenFlow Biosciences
- Modality
- Gene Therapies, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
SIRT6c is a gene therapy based on a naturally occurring human sirtuin 6 (SIRT6) variant (containing two point mutations, N308K and A313S) identified in centenarians. This variant exhibits enhanced mono-ADP-ribosyltransferase activity, improved DNA double-strand break repair, and superior genomic stability compared to wild-type SIRT6. Developed by Genflow Biosciences, SIRT6c is being evaluated across multiple modalities, including plasmid DNA (pDNA) and adeno-associated virus (AAV8) vectors for veterinary applications (such as sarcopenia and longevity in aged dogs), and mRNA-lipid nanoparticle (mRNA-LNP) formulations for human indications, including metabolic dysfunction-associated steatohepatitis (MASH) and ophthalmology (such as glaucoma).
- Other names
- AAV8-CMV-SIRT6cAAV-8-CMV-SIRT6cAAV 8-CMV-SIRT6cSIRT6 centenarian variantSIRT-6 centenarian variantSIRT 6 centenarian variantSIRT6c gene therapySIRT-6c gene therapySIRT 6c gene therapycentenarian SIRT6centenarian SIRT6 variantpDNA-SIRT6cpDNA-SIRT-6cpDNA-SIRT 6c
02
Targets
NAD (Nicotinamide adenine dinucleotide)H3 (Histone H3.2)
Beyond the preview
Go deeper on SIRT6c.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SIRT6c.